Status:

COMPLETED

A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)

Lead Sponsor:

Bruce Brew

Collaborating Sponsors:

ViiV Healthcare

Conditions:

Human Immunodeficiency Virus (HIV)

HIV Associated Neurocognitive Disorders (HAND)

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

HIV related cognitive impairment still occurs despite highly active antiretroviral therapy (HAART). HIV disease affects the brain in 20-40% of patients with advancing HIV disease; leading to varying d...

Eligibility Criteria

Inclusion

  • HIV Positive
  • On HAART, with plasma viral load \< 50 copies/ml for previous 12 months or more
  • Able to provide informed consent
  • HAND diagnosis, with symptom progression within previous 6 months

Exclusion

  • Non-HIV related neurological disorders and active central nervous system (CNS) opportunistic infection (as assessed by full blood count, electrolytes, creatinine, glucose, liver funciton tests, cryptococcal antigen, venereal disease research laboratory (VDRL), MRI brain scan and CSF analysis for cell count, protein, glucose, culture, VDRL and cryptococcal antigen)
  • Psychiatric disorders on the psychiatric axis
  • Current major depression
  • Current substance use disorder, or severe substance use disorder within 12 months of study entry
  • Active Hepatitis C Virus (HCV) (detectable HCV RNA)
  • History of loss of consciousness \> 1 hour
  • Non-proficient in English
  • Medications known to pharmacologically interact with antiretrovirals (ARVs)
  • Currently taking an entry inhibitor
  • Pregnancy (as assessed by the urine pregnancy test)

Key Trial Info

Start Date :

October 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2014

Estimated Enrollment :

19 Patients enrolled

Trial Details

Trial ID

NCT01449006

Start Date

October 1 2011

End Date

September 1 2014

Last Update

February 27 2019

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

St. Vincent's Hospital

Sydney, New South Wales, Australia, 2010

2

The Alfred Hospital

Melbourne, Victoria, Australia, 3181